Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1565 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Dafna D. Gladman¹, Vibeke Strand², Arthur Kavanaugh³, Philip J. Mease⁴, Christopher J. Edwards⁵, Maurizio Cutolo⁶, Frédéric Lioté⁷, Paul Bird⁸, Randall M. Stevens⁹, Lichen Teng⁹, Marla Hochfeld⁹ and Georg A. Schett¹⁰, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Stanford University, Portola Valley, CA, ³University of California San Diego, La Jolla, CA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University Hospital Southampton, Southampton, United Kingdom, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁷Rheumatology Department, University Paris Diderot, Paris, France, ⁸Combined Rheumatology Practice, Kogarah, Australia, ⁹Celgene Corporation, Warren, NJ, ¹⁰Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Jonathan Kay¹, Roy Fleischmann², Edward C. Keystone³, Elizabeth C. Hsia^4,5, Neil Goldstein⁴, Benjamin Hsu⁴, Yiying Zhou⁴, Jürgen Braun⁶ and Arthur Kavanaugh⁷, ¹UMass Memorial Medical Center, Worcester, MA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷University of California San Diego, La Jolla, CA
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…
Abstract Number: 1564 • 2014 ACR/ARHP Annual Meeting
Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension
Philip J. Mease¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephan Hall⁵, Arthur Kavanaugh⁶, Eric Lespessailles⁷, Georg A. Schett⁸, Kamal Shah⁹, Randall M. Stevens⁹, Lichen Teng⁹ and Jürgen Wollenhaupt¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Sheffield, Sheffield, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁵Cabrini Health and Monash University, Melbourne, Australia, ⁶University of California San Diego, La Jolla, CA, ⁷University of Orléans, Orléans, France, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), a phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE 1,…
Abstract Number: L1 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Iain B. McInnes^1,2, Philip J. Mease³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Christopher T. Ritchlin⁶, Proton Rahman⁷, Désirée van der Heijde⁸, Robert B. M. Landewé⁹, Philip G. Conaghan¹⁰, Hanno Richards¹¹, Gregory Ligozio¹², Luminita Pricop¹³ and Shephard Mpofu¹⁴, ¹University of Glasgow, Glasgow, Scotland, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Memorial University, St John's, NF, Canada, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹³Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a human anti–IL-17A monoclonal antibody, has shown efficacy in the treatment of psoriasis in phase 3 studies with subcutaneous (s.c.) dosing as well…
Abstract Number: 3010 • 2014 ACR/ARHP Annual Meeting
The Development and Evaluation of a Self-Monitoring and Patient-Initiated Follow-up Service for People with Rheumatoid or Psoriatic Arthritis on Methotrexate
Hayley McBain^1,2, Michael Shipley³, Abigail Olaleye³, Samantha Moore⁴, Shashi Hirani⁵ and Stanton Newman⁶, ¹Health Services Research and Management Division, City University London, London, United Kingdom, ²Community Health Newham, East London Foundation Trust, London, United Kingdom, ³University College Hospital London, London, United Kingdom, ⁴Rheumatology, University College London, London, United Kingdom, ⁵City University London, London, United Kingdom, ⁶School of Community & Health Sciences, City University London, London, United Kingdom
Background/Purpose: Patient-initiated services in rheumatology have been found to be cost-saving without compromising the clinical or psychosocial well-being of patients with rheumatoid arthritis. Self-monitoring is…
Abstract Number: 1579 • 2014 ACR/ARHP Annual Meeting
Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Dafna D. Gladman², Arthur Kavanaugh³, Adewale O. Adebajo⁴, Juan Gomez-Reino⁵, Jurgen Wollenhaupt⁶, Georg A. Schett⁷, Kamal Shah⁸, ChiaChi Hu⁸, Randall M. Stevens⁸, Christopher Edwards⁹ and Charles A. Birbara¹⁰, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of California San Diego, La Jolla, CA, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Schön-Klinik, Hamburg, Germany, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Warren, NJ, ⁹Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁰University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is a PDE4 inhibitor that helps regulate the immune response. PALACE 1, 2, and 3 assessed the efficacy and safety of APR…
Abstract Number: L22 • 2014 ACR/ARHP Annual Meeting
Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)
Alvin Wells¹, Christopher Edwards², Adewale O. Adebajo³, Alan J. Kivitz⁴, Paul Bird⁵, Kamal Shah⁶, ChiaChi Hu⁶, Randall M. Stevens⁶ and Jacob A. Aelion⁷, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University Hospital Southampton, Southampton, United Kingdom, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Sydney, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes joint inflammation and other manifestations of psoriatic arthritis…
Abstract Number: 2970 • 2014 ACR/ARHP Annual Meeting
Psoriatic Arthritis is Associated with Heterotopic Ossification after Total Hip Arthroplasty
Mario Cedillo¹, Arielle Fein², Susan M. Goodman³, Rebecca Zhu⁴, Mark P. Figgie⁵, Michael Alexiades⁶, Jayme C. Burket⁷ and Lisa A. Mandl³, ¹Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Clinical Research, Hospital for Special Surgery, New York, NY, ⁵Orthopedics, Hospital for Special Surgery, New York, NY, ⁶Orthopaedics, Hospital for Special Surgery, New York, NY, ⁷Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: Heterotopic ossification (HO), the pathologic deposition of ectopic bone in soft tissues, is a feared complication of total hip arthroplasty (THA). HO is strongly…
Abstract Number: 1544 • 2014 ACR/ARHP Annual Meeting
Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients Comorbid with Psoriatic Arthritis
Steven R Feldman¹, Yang Zhao², Lizheng Shi³, Jackie Lu² and MaryHelen Tran², ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Tulane University, New Orleans, LA
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with substantial economic and comorbidity burdens. However, the burden among PsO patients comorbid with PsA has…
Abstract Number: 2443 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Coronary Heart Disease In Spondyloarthopathies may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center
Trayton Mains¹ and Vikas Majithia², ¹University of Mississippi Medical Center, Jackson, MS, ²G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS
Background/Purpose: An increased prevalence of cardiovascular disease (CVD) and coronary heart disease (CHD) has been reported in patients with spondyloarthritides (SpA). This study investigated the…
Abstract Number: 348 • 2013 ACR/ARHP Annual Meeting
Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Dafna D. Gladman⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California San Diego, San Diego, CA, ³Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and…
Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting
Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab
Rene Westhovens¹, Clifton O. Bingham III², Michael E. Weinblatt³, Roy Fleischmann⁴, Edward C. Keystone⁵, Elizabeth C. Hsia⁶, Benjamin Hsu⁶, Lilianne Kim⁶, Surekha Mudivarthy⁶, Michael Mack⁷, Neil Goldstein⁶, Jürgen Braun⁸, Arthur Kavanaugh⁹, Alan M. Mendelsohn¹⁰ and Jonathan Kay¹¹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸PsAID taskforce, EULAR, Zurich, Switzerland, ⁹University of California San Diego, San Diego, CA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
Abstract Number: 350 • 2013 ACR/ARHP Annual Meeting
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Structural destruction in peripheral joints may occur over time in both PsA and RA. We previously reported that 47% of early PsA patients treated…
Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting
COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Siva Narayanan¹, Yao Lu², Richard Hutchings² and Amanda Baskett², ¹Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, ²Ipsos Healthcare, London, United Kingdom
Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].